Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11988217 | 0.88 | PLG (0.35) | PLGIRAK4PDCD1LG2CD274CTSD | |
| SCHEMBL855693 | 0.88 | PLG (0.35) | PLGIRAK4PDCD1LG2CD274CTSD | |
| SCHEMBL13483942 | 0.88 | PLG (0.35) | PLGIRAK4PDCD1LG2CD274CTSD | |
| SCHEMBL20760456 | 0.79 | — | — | |
| SCHEMBL14285557 | 0.78 | — | — | |
| SCHEMBL94282 | 0.78 | — | — | |
| SCHEMBL24004296 | 0.78 | CD274 (0.39) | PDCD1LG2CD274 | |
| SCHEMBL24004310 | 0.78 | CD274 (0.39) | PDCD1LG2CD274 | |
| SCHEMBL5992949 | 0.77 | IRAK4 (0.37) | IRAK4PDCD1LG2CD274CTSD | |
| SCHEMBL16611587 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | PLG 1052/4885IRAK4 4803/4885PDCD1LG2 3792/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | PLG 1052/4885IRAK4 4803/4885PDCD1LG2 3792/4885 |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | PLG 1569/4885IRAK4 4727/4885PDCD1LG2 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.